THE ADRENERGIC RECEPTORS ([ALPHA] .sub.1.-, [alpha] .sub.2.-, [beta] .sub.1.-, AND [beta] .sub.2.-), which mediate the physiological effects of catecholamines, belong to the family of plasma membrane receptors that are coupled to guanine nucleotide regulatory proteins (G proteins) (1). This receptor family also includes rhodopsin and the visual color opsins, the muscarinic cholinergic receptors, and many other neuro-transmitter receptors and receptors for peptide hormones. A common feature of G protein-coupled receptors is that agonist occupancy of t he receptor leads to receptor activation of a G protein, which in turn modulates the activity of an effector enzyme or ion channel. Several of the G protein-coupled receptors (including the major subtypes of adrenergic receptors) have been cloned and found to share structural features with rhodopsin (2). The most consistently conserved of these features is the existence of seven clusters of hydrophobic amino acids. In addition, there is significant amino acid sequence similarity among these receptors, which is most striking in the hydrophobic domains. For bovine rhodopsin, physical and biochemical studies have revealed that these hydrophobic domains may form seven alpha helices that span the lipid bilayer (3). It has been suggested that these alpha helices form a pocket for the chromophore 11-cis-retinal (3). Thus, in an analogous fashion, the hydrophobic domains of the adrenergic receptors may form a pocket in the plasma membrane for binding ligands.
Because so many different hormones, neurotransmitters, and drug receptors are likely to have structures homologous with the adrenergic receptors, it is necessary to achieve an understanding of the structural basis for the various functional properties of these receptors, in particular the specificity of ligand binding and effector coupling. This has been done heretofore (i) by mutagenesis, especially the deletion of specific peptide sequences (4-6), and (ii) biochemically, where proteases have been used to cleave defined peptide segments from the digitonin solubilized receptor (7). These methods, although useful in delineating regions of the receptor that do not influence its function, suffer from difficulties in that it is difficult to draw compelling inferences about the role of specific domains based on loss of functions.
In order to circumvent such problems, and to establish a potentially general approach to the study of G protein-coupled receptors so that positive inferences can be drawn about functions associated with specific receptor domains, we have constructed and expressed a series of chimeric [alpha] (Fig. 3 ) and CR 9 bound [.sup.3 .H]yohimbine with an affinity high enough to permit determination of affinity constants for agonists and antagonists (Table 3 ).
The ability of each chimeric receptor to couple to Gs and thus activate adenylyl cyclase was determined by studying epinephrine-stimulated adenylyl cyclase activity in oocyte membranes expressing the chimeric receptor. Control oocyte membranes exhibited little or no epinephrine-stimulated adenylyl cyclase activity. Epinephrine was used because it is an agonist for both [alpha] .sub.2.-AR and [beta].sub.2.-AR, and thus would be expected to act as an agonist for an [alpha] .sub.2.-[beta].sub.2.-chimeric receptor. Chimeric receptors 1, 2, 6, 8, and 9 were capable of activating adenylyl cyclase while CR's 3, 4, 5, 7, and 10 were not. An epinephrine dose response study was done to determine the efficiency of agonist stimulated receptor activation of adenylyl cyclase for CR's 1, 2, 6, 8, and 9 relative to the [beta].sub.2.-AR (Fig. 4 and Table 2 ). The agonist potency for adenylyl cyclase stimulation of each chimeric receptor was determined from results of isoproterenol, epinephrine, and p-aminoclonidine dose response studies on each chimeric receptor capable of mediating epinephrine-stimulatable adenylyl cyclase activity ( Fig. 5  and (Fig. 6) , these deletions would correspond to amino acid 222 to 229 and amino acid 258 to 270, respectively. These studies therefore provide clues to the potential sites of interaction between the [beta].sub.2.-AR and G.sub.s.; however, it is also possible that the negative effect of these deletion mutations might be due to an allosteric rather than a direct effect on the actual G protein coupling domain.
Proteolysis studies on the turkey [beta]-AR suggest that deletion of even larger regions of the third cytoplasmic loop, and possibly of the fifth hydrophobic domain, do not affect the ability of the receptor to couple to G.sub.s (7). However, with this approach it was difficult to define the precise position of some of the proteolytic cleavage sites. Our date on the chimeric receptors, in particular the ligand binding properties of CR 9, suggest that the sixth hydrophobic domain does not exert a major influence on either agonist or antagonist order of potency. However, the seventh hydrophobic domain appears to be a major determinant of both agonist and antagonist ligand binding Chimeric alpha-2-,beta-2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Fig. 1C ), one encoding amino acid 1 to 262, containing hydrophobic domains 1 to 5, SR(1-5), and the other containing hydrophobic domains 6 to 7, SR(6-7). We constructed SR(1-5) by inserting a termination codon after amino acid 262. This mutant does not bind ligands or activate adenylyl cyclase (10). We made SR(6-7) by deleting the region between the second amino acid of the 
Chimeric alpha-2-,beta-2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Chimeric receptor 8 is of particular interest, therefore, since it contains two molecular splice junctions, yet has a higher affinity for epinephrine (Tables 1 and 3 ) and is more efficient at activating adenylyl cyclase (Table 2 ) than either CR 2 or CR 6, each of which contains only one of the two molecular splice junctions found in CR 8 (Fig. 1) . This observation might be explained by considering the possible arrangement of hydrophobic domains in the [alpha] .sub.2.-AR and various chimeric receptors (Fig. 8) 
